| 1.18 0 (0%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.56 |
1-year : | 1.82 |
| Resists | First : | 1.34 |
Second : | 1.56 |
| Pivot price | 1.24  |
|||
| Supports | First : | 1.12 |
Second : | 1 |
| MAs | MA(5) : | 1.18 |
MA(20) : | 1.25 |
| MA(100) : | 1.33 |
MA(250) : | 1.39 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 53.6 |
D(3) : | 49.8 |
| RSI | RSI(14): 42.7 |
|||
| 52-week | High : | 1.77 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARTL ] has closed above bottom band by 21.4%. Bollinger Bands are 6.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.23 - 1.24 | 1.24 - 1.24 |
| Low: | 1.17 - 1.17 | 1.17 - 1.18 |
| Close: | 1.17 - 1.18 | 1.18 - 1.19 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Wed, 11 Sep 2024
ARTL stock touches 52-week low at $1.12 amid market challenges - Investing.com Australia
Tue, 10 Sep 2024
ARTL stock touches 52-week low at $1.12 amid market challenges - Investing.com
Wed, 04 Sep 2024
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Tue, 16 Jul 2024
Artelo’s FABP5 inhibitor cleared to enter clinic for chemotherapy-induced peripheral neuropathy - BioWorld Online
Mon, 01 Nov 2021
Hot Reddit Penny Stocks to Watch That Exploded Today - Penny Stocks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 1 (K) |
| EPS | -3.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -54.4 % |
| Return on Equity (ttm) | -88.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.36 |
| PEG Ratio | 0 |
| Price to Book value | 0.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|